Shares of Regentis, a micro-cap implant developer, have soared by 500%. What’s behind this?

Shares of Regentis Biomaterials, an Israeli developer of implants for bone and cartilage regeneration, soared nearly 527% on June 15 on the New York Stock Exchange, reaching an all-time high. The company canceled the sale of additional shares, which it had announced on May 1.

Regentis shares surged nearly 527% on June 15, reaching $9.40. This marks an all-time high. During trading on June 15, the stock rose by more than 850%, according to the Stocktwits portal.

Investors reacted to Regentis’s withdrawal of its registration statement for additional shares, which it had filed with the U.S. Securities and Exchange Commission (SEC).

On May 1, the company announced plans to sell 3.3 million shares at $3 each—for a total of $10 million before expenses. It intended to use the proceeds to fund further research into its products. In documents filed with the regulator on June 15, Regentis stated that it no longer plans to sell additional shares. Thus, the stakes of existing investors will not be diluted.

Regentis develops products for tissue repair. Its flagship product is called GelrinC, a biodegradable hydrogel implant. Here’s how it works: the product is injected with a syringe, for example, into the knee joint. There, it breaks down and dissolves, thereby allowing the surrounding cells to regenerate the cartilage.

In the U.S. alone, Regentis’ target market is estimated at $3 billion, and there are currently no ready-to-use treatments available in the country, the company notes.

GelrinC is currently in the clinical trial phase in the U.S. and has been approved for use in Europe. In the third quarter, the company plans to begin training surgeons in the use of its drug. This is part of the work to prepare for commercialization, according to its press release. The day after its publication, on June 9, Regentis’s stock price soared by 88%.

Regentis went public on the New York Stock Exchange in December 2025, offering investors 1.25 million shares at $8 each. Since then—thanks to the rally on June 15—the stock price has risen by 27%.

Only one Wall Street analyst covers the company. He recommends buying its stock, with a target price of $10. This represents growth potential of just over 6% from the last closing price.